206 related articles for article (PubMed ID: 22843108)
1. Formoterol concentrations in blood and urine: the World Anti-Doping Agency 2012 regulations.
Eibye K; Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2013 Jan; 45(1):16-22. PubMed ID: 22843108
[TBL] [Abstract][Full Text] [Related]
2. Urine concentrations of repetitive doses of inhaled salbutamol.
Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Int J Sports Med; 2011 Aug; 32(8):574-9. PubMed ID: 21563035
[TBL] [Abstract][Full Text] [Related]
3. Quantitative detection of inhaled formoterol in human urine and relevance to doping control analysis.
Deventer K; Pozo OJ; Delbeke FT; Van Eenoo P
Drug Test Anal; 2012 Jun; 4(6):449-54. PubMed ID: 22447497
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetic profile of inhaled and oral salbutamol in elite athletes with asthma and nonasthmatic subjects.
Elers J; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Clin J Sport Med; 2012 Mar; 22(2):140-5. PubMed ID: 22388343
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the urinary threshold concentration of formoterol in sports drug testing.
Ventura R; Damasceno LM; Ramírez R; Farré M; Bergés R; Segura J
Drug Test Anal; 2013 Apr; 5(4):266-9. PubMed ID: 23355217
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of a ultra high performance liquid chromatography-tandem mass spectrometric method for the direct detection of formoterol in human urine.
Sardela VF; Deventer K; Pereira HM; de Aquino Neto FR; Van Eenoo P
J Pharm Biomed Anal; 2012 Nov; 70():471-5. PubMed ID: 22841556
[TBL] [Abstract][Full Text] [Related]
7. Enantioselective disposition of (R,R)-formoterol, (S,S)-formoterol and their respective glucuronides in urine following single inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Walters EH
Drug Test Anal; 2019 Jul; 11(7):950-956. PubMed ID: 30865387
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of salmeterol and its main metabolite α-hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control.
Jessen S; Becker V; Rzeppa S; Backer V; Bengtsen KH; Hullstein I; Dehnes Y; Hostrup M
Drug Test Anal; 2021 Apr; 13(4):747-761. PubMed ID: 33210444
[TBL] [Abstract][Full Text] [Related]
9. Medical and pharmacological approach to adjust the salbutamol anti-doping policy in athletes.
Pillard F; Lavit M; Cances VL; Rami J; Houin G; Didier A; Rivière D
Respir Res; 2015 Dec; 16():155. PubMed ID: 26704899
[TBL] [Abstract][Full Text] [Related]
10. A simplified procedure for the analysis of formoterol in human urine by liquid chromatography-electrospray tandem mass spectrometry: application to the characterization of the metabolic profile and stability of formoterol in urine.
Mazzarino M; de la Torre X; Fiacco I; Pompei C; Calabrese F; Botrè F
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Jul; 931():75-83. PubMed ID: 23777613
[TBL] [Abstract][Full Text] [Related]
11. Impact of ethnicity, gender, and dehydration on the urinary excretion of inhaled salbutamol with respect to doping control.
Dickinson J; Hu J; Chester N; Loosemore M; Whyte G
Clin J Sport Med; 2014 Nov; 24(6):482-9. PubMed ID: 24518370
[TBL] [Abstract][Full Text] [Related]
12. The influence of exercise and dehydration on the urine concentrations of salbutamol after inhaled administration of 1600 µg salbutamol as a single dose in relation to doping analysis.
Haase CB; Backer V; Kalsen A; Rzeppa S; Hemmersbach P; Hostrup M
Drug Test Anal; 2016 Jul; 8(7):613-20. PubMed ID: 26044066
[TBL] [Abstract][Full Text] [Related]
13. Blood and urinary concentrations of salbutamol in asthmatic subjects.
Elers J; Pedersen L; Henninge J; Lund TK; Hemmersbach P; Dalhoff K; Backer V
Med Sci Sports Exerc; 2010 Feb; 42(2):244-9. PubMed ID: 19927035
[TBL] [Abstract][Full Text] [Related]
14. Can asthma treatment in sports be doping? The effect of the rapid onset, long-acting inhaled beta2-agonist formoterol upon endurance performance in healthy well-trained athletes.
Carlsen KH; Hem E; Stensrud T; Held T; Herland K; Mowinckel P
Respir Med; 2001 Jul; 95(7):571-6. PubMed ID: 11453313
[TBL] [Abstract][Full Text] [Related]
15. Enantioselective disposition of (R)-salmeterol and (S)-salmeterol in urine following inhaled dosing and application to doping control.
Jacobson GA; Hostrup M; Narkowicz CK; Nichols DS; Haydn Walters E
Drug Test Anal; 2017 Aug; 9(8):1262-1266. PubMed ID: 28033454
[TBL] [Abstract][Full Text] [Related]
16. Urine and serum concentrations of inhaled and oral terbutaline.
Elers J; Hostrup M; Pedersen L; Henninge J; Hemmersbach P; Dalhoff K; Backer V
Int J Sports Med; 2012 Dec; 33(12):1026-33. PubMed ID: 22782385
[TBL] [Abstract][Full Text] [Related]
17. Olodaterol and vilanterol detection in sport drug testing.
Chundela Z; Große J
Drug Test Anal; 2015; 7(11-12):980-2. PubMed ID: 26593301
[TBL] [Abstract][Full Text] [Related]
18. Beta2-adrenoceptor regulation and bronchodilator sensitivity after regular treatment with formoterol in subjects with stable asthma.
Aziz I; Hall IP; McFarlane LC; Lipworth BJ
J Allergy Clin Immunol; 1998 Mar; 101(3):337-41. PubMed ID: 9525449
[TBL] [Abstract][Full Text] [Related]
19. Monitoring 2-phenylethanamine and 2-(3-hydroxyphenyl)acetamide sulfate in doping controls.
Sigmund G; Dib J; Tretzel L; Piper T; Bosse C; Schänzer W; Thevis M
Drug Test Anal; 2015; 7(11-12):1057-62. PubMed ID: 26481102
[TBL] [Abstract][Full Text] [Related]
20. Beta2-Agonist Doping Control and Optical Isomer Challenges.
Jacobson GA; Fawcett JP
Sports Med; 2016 Dec; 46(12):1787-1795. PubMed ID: 27164986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
